Infosys seems to struggle to convert their large deals into immediate revenue growth. While they secured an impressive number of big contracts (90 deals valued at $17.7bn), this hasn’t translated into the strong financial performance they expected in the last quarter.
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally.
Reported revenues at ₹37,923 crores, with a growth of 1.3% Y/Y. Revenues in CC terms remained flat YoY and declined by 2.2% Q/Q. Operating margin at 20.1%, a decline of 0.9% Y/Y and 0.4% Q/Q, and Basic EPS at ₹19.25, with an increase of 30.2% Y/Y. FCF at ₹7,032 crore, a growth of 20.3% Y/Y; FCF conversion at 88.2% of net profit .
Infosys stock price increased by 11.68% in the past 1-year. The stock has a 52-week high of ₹1,733 and its 52-week low is ₹1,262.25. The stock price showed a downward trend in the past 3-months period and gave ~(12%)returns.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
https://www.crispidea.com/report/infosys-equity-report-q3-24/
$272.00
Scan this QR code using your UPI app.
Amount: ₹499
malay.ia@validhdfc
After payment, email your transaction ID or payment confirmation to [email protected] , along with your name and email address. We'll verify your payment and email the report.
STMicroelectronics N.V. Q3FY26 - ST is expanding its supply of optical transceivers and power chips to cloud datacenter builders.
$240.00
Meta Platforms, Inc (Q3FY26) - Meta delivered Q3FY26 revenue of $64.6bn, up 26% YoY, with ad revenue of $63.1bn also up 26% on a constant currency basis.
$240.00
General Dynamics Corporation Q3FY26 - During 9MFY26, the aerospace and defense sector delivered high single digit top line growth YoY, supported by steady European defense rearmament and solid demand for commercial airframes.
$240.00
Twist Bioscience Corporation (Q3FY26) - Twist’s revenue expansion is primarily driven by volume gains across its Next-Generation Sequencing (NGS) target enrichment panels and synthetic biology tools.
$224.00
Capital Deployment - 2026 highlights key themes including the move away from physical assets and bank deposits towards equity and alternative investments, the democratization of high-yield asset classes through technology, and the surge in retail participation driven by mobile-first platforms and open banking infrastructure.
$225.00
A new Samvat brings fresh opportunities, and new questions for investors. As market conditions shift and valuations reset, which stocks deserve a place on your watchlist? Discover 10 research-backed stock ideas for Samvat 2083, selected through CrispIdea’s multi-factor scoring model and analysed for earnings potential, business fundamentals and valuation.
₹499.00
The Consumerization of Healthcare - 2026: Gen Z and younger Millennials are fundamentally rewriting the rules of healthcare. Instead of relying on a primary care physician as the first point of contact, their healthcare journey now begins with a TikTok video, a Reddit thread, or a conversation with an AI chatbot.
$850.00
The Magnificent Seven: H1 2026 Performance - The consolidated YTD 2026 performance highlights a positive yet uneven trajectory across the mega-cap technology universe, with returns concentrated among a few leading names.
$125.00